AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 176.72B |
| Revenue (ttm) | 41.24B |
| Net Income (ttm) | 6.05B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.87 |
| PE Ratio | 29.41 |
| Forward PE | 15.92 |
| Dividend | 2.34 (2.07%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,383,351 |
| Average Volume | 1,622,611 |
| Open | 11,338 |
| Previous Close | 11,346 |
| Day's Range | 11,246 - 11,400 |
| 52-Week Range | 9,574 - 12,256 |
| Beta | 0.17 |
| RSI | 41.34 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Trial
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Trial
AstraZeneca fails to meet main goal in lung disease trial
AstraZeneca’s Fasenra misses primary endpoint in COPD late-stage trial. Read more here.
AstraZeneca posts late-stage trial win for injectable Saphnelo in SLE
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Results for Saphnelo
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Results for Saphnelo
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the...
AstraZeneca's asthma drug fails main goal of COPD study
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
Notable ETF Inflow Detected - SPDW, ASML, SAP, AZN
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain | Polly Toynbee
The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him Governing in the era of Donald Trump has been Labour’s...
Big pharma firms have paused nearly £2bn in UK investments this year
Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears Big pharmaceutical companies have ditched or paused nearly £2bn in planned UK investments so ...
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc (NASDAQ: AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site. AstraZeneca spokesperson told Reuters the company regular...
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in ...
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
How the UK fell out with big pharma
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...
AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty
AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty
AstraZeneca's £200m blow to Labour as pharma giant scraps major investment
Hours after official figures showed output from the pharmaceuticals industry in the UK fell 4.5 per cent in July, Britain's biggest firm said the project at its research site has been 'paused'.
AstraZeneca pauses £200m expansion in Cambridge
It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.
AstraZeneca pauses £200m Cambridge investment
Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.
AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty
AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty
AstraZeneca (AZN) Halts Major Investment in UK Research Facility
AstraZeneca (AZN) Halts Major Investment in UK Research Facility
AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty
AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whic...
AstraZeneca follows Merck’s pullback in Britain: report
AstraZeneca pauses £200m investment in Cambridge research site
Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding The drugmaker AstraZeneca has paused a planned £200m investment in its Cambridge research site, co...
Exclusive: AstraZeneca pauses $270 million investment in Britain
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit...
AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment
AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment